With no cure in sight, drugs firm LianBio begins exit strategy 研发及商业化能力不足，联拓生物将从美股退市
The biotech, which obtained rights to novel drugs for use in the Chinese market, has announced a plan to wind up its business and delist from the Nasdaq just four years after being founded. 这家专注药物授权引进模式的药企，成立四年来仍没有一款走向市场的产品，最近更宣布在今年底之前退市。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.